Nutrients, Vol. 17, Pages 3789: The Effect of a Low-Energy and Low-Glycemic Diet on Adipose Tissue Metabolism and Energy Expenditure in Women with Excess Body Weight
Nutrients, Vol. 17, Pages 3789: The Effect of a Low-Energy and Low-Glycemic Diet on Adipose Tissue Metabolism and Energy Expenditure in Women with Excess Body Weight Nutrients doi: 10.3390/nu17233789 Authors: Ewa Lange Ewelina Pałkowska-Goździk Background/Objectives: Data indicate that a low-glycemic index diet may be an effective nutritional approach to improve cardiometabolic parameters and support weight […]
GLP-1 drugs alone aren’t a magic fix — My patient’s story shows what really works
Post Content
WHO issues guidelines on GLP-1 therapies for obesity treatment: Understanding the impact, safety considerations, and who can benefit
This week, the World Health Organization entered a new arena with its first global guideline on GLP-1 therapies for obesity treatment. Released on December 1, 2025, the document conditionally recommends drugs like semaglutide, liraglutide, and tirzepatide for adults with a BMI of 30 or higher-but only as part of a lifelong plan that pairs them […]
Suicidal Thoughts Prompt New Warnings From Health Authorities For GLP-1 Drugs
Talk to your doctor.
GLP-1 Drugs for Cats? High-Dose Wegovy Heads to FDA; Smartphone-Obesity Link in Kids
(MedPage Today) — Weight-loss injectables for pets? Okava Pharmaceuticals announced plans to kick off a pilot study of a GLP-1 drug for cats with obesity. (New York Times) Novo Nordisk submitted a higher-dose version of semaglutide (Wegovy) to…
GLP-1 drugs may reach fewer than one in 10 people who need them, experts predict
The World Health Organization (WHO) has announced its official guidance on the use of GLP-1 drugs for treating obesity. GLP-1 drugs are medications that mimic the natural hormone glucagon-like peptide-1 (GLP-1), which are most commonly used for type 2 diabetes and medical weight loss. The first guideline, released on Dec. 1, aims to address the […]
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer’s trials
Despite a lack of results from the trials, the Vice President of the company says “we still think it was the right decision.”
WHO backs GLP-1 meds like Ozempic to treat obesity
The World Health Organization is backing GLP-1 medications for the treatment of obesity, which some advocates hope will open up access to the drugs and improve affordability. Brands such as Ozempic and Wegovy are already wildly popular in North America. »»» Subscribe to CBC News to watch more videos: http://bit.ly/1RreYWS For breaking news, video, audio […]
WHO Issues First-Ever Guidelines for Use of GLP-1 Drugs to Treat Obesity
The WHO recommended GLP-1s as a treatment for obesity alongside a healthy diet and regular exercise. Milles Team/Stocksy New guidelines from the World Health Organization (WHO) recommend using GLP-1 medications to help manage obesity. The agency said the weight-loss drugs should be used in conjunction with a healthy diet and regular exercise. Experts say the […]
A genetic screen in enteroendocrine cells reveals mechanisms that control protein sensing and GLP-1 release
Enteroendocrine cells (EECs) are the principal nutrient sensors in the gastrointestinal (GI) tract and release hormones such as glucagon-like-peptide 1 (GLP-1) that modulate GI function and appetite. While some of the molecules involved in nutrient sensing within EECs have been described, there have been no systematic studies to map the relevant genes and pathways. Here, […]